REFRACTORY HEPATOCELLULAR CARCINOMA
Clinical trials for REFRACTORY HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo takes on tough liver cancers
Disease control Recruiting nowThis study tests whether combining two drugs, ligufalimab and cadonilimab, can shrink tumors in people with advanced liver or bile duct cancers that no longer respond to standard treatments. About 64 adults will receive the drug combination to see if it improves response rates an…
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for young cancer patients: experimental drug targets tough tumors
Disease control Recruiting nowThis study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …
Matched conditions: REFRACTORY HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated May 06, 2026 16:01 UTC